



## ASX ANNOUNCEMENT

### Change To Lumos Board

**Melbourne, VIC. (11 February 2022)** - Lumos Diagnostics (ASX:LDX, “Lumos” or the “Company”), a leader in rapid point-of-care (POC) diagnostic technologies, has today announced that Rob Sambursky has resigned from the Lumos Board of Directors to focus on the management of the Company’s operations as Chief Executive Officer (CEO). There are no changes to Mr Sambursky’s current remuneration terms.

In view of these increasing operational demands, Rob has elected to step down from Board to focus on activities that will support progressing high-impact commercial opportunities. This demand is driven from the growth in global demand for point-of-care diagnostic test development services combined with the recent increase in the Company’s contract manufacturing capacity and expansion of Lumos’ own diagnostic product pipeline. Pleasingly, this has culminated in a range of different commercial opportunities that will benefit from Rob’s full-time operation focus.

In the immediate term, these include managing the material orders currently being received from Canada for the CoviDx™ test, and overseeing the application for U.S. regulatory clearance of lead product, FebriDx®, that is currently under review with the FDA.

“On behalf of the Board, I would like to thank Rob for his significant contribution to the Board of Directors of Lumos, including steering the Company through listing on the ASX in 2021 and navigating the operational challenges that we have faced over the past two years as a result of the global COVID-19 pandemic,” said Lumos’ Executive Chairman Sam Lanyon.

This announcement was approved by the Lumos Disclosure Committee.

###

#### About Lumos Diagnostics

Lumos Diagnostics specialises in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercialises novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit [lumosdiagnostics.com](https://lumosdiagnostics.com) or call +1 941-556-1850.

**Forward-Looking Statements**

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

**Media Contact:**

Matthew Wright – Australia  
Director, NWR Communications  
matt@nwrcommunications.com.au  
+61 (0) 451 896 420

**Investor Contact:**

Matthijs Smith – Lumos Diagnostics  
ir@lumosdiagnostics.com  
+61 411 137 080  
+61 3 9087 1598

**Company Registered Office:**

Lumos Diagnostics Holdings Ltd  
Level 4, 100 Albert Rd  
South Melbourne, VIC 3205  
+61 3 9087 1598